Vitamin K Antagonist Treatment Burden Assessed with the Patient Reported Outcome "Anti Clot Treatment Scale": KAFe Trial, a Single-Center Study Involving 202 Patients.

Vitamin K antagonists (VKAs) remain essential in selected patients requiring anticoagulation. Patient satisfaction, essential for adherence and outcomes, can be evaluated using the Anti-Clot Treatment Scale (ACTS).In the prospective, single-center KAFe trial, 202 patients on VKA therapy attending the Ferrara Hematology Center were enrolled in January-March 2025. Clinical and demographic data were collected, and ACTS was administered during routine INR monitoring.Highly satisfied patients were more frequently male, older, and had an ECOG performance status ≥1. In multivariate analysis, male sex (OR 1.8) and ECOG ≥1 (OR 2.1) independently predicted higher satisfaction.ACTS benefit scores were consistently high across the cohort, whereas burden scores varied according to age, sex, ECOG status, history of venous thrombosis, and duration of VKA therapy.Incorporating ACTS into routine practice may support patient-centered counseling and shared anticoagulation decisions.